Cellistic traces its origin to a single imperative: to invent and advance the technologies that enable cell therapy to reach its full potential. Through facilities purpose-built for that mission, we help clients de-risk and accelerate the development of novel cell therapies through both cell line development and manufacturing of iPSC-derived immunotherapies.
Our cell line development expertise helps drive clients from an idea to an edited iPSC, leveraging precise and proven reprogramming, gene editing, and cell banking technologies along the way in a shortened timeframe.
Our cell therapy manufacturing capabilities are centered on a highly efficient family of established manufacturing processes for NK cells, α/β T cells, γ/δ T cells, macrophages, and other related lineages.
The combination of these two platforms ensures the highest quality starting cells are scaled and transformed as quickly as possible into clinic-ready allogeneic drug product for our clients.